期刊
NEUROPSYCHOPHARMACOLOGY
卷 38, 期 5, 页码 802-816出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2012.245
关键词
D-amphetamine; intermediate phenotype; candidate gene; genetic association; replication
资金
- NIH [DA007255, DA02812, DA021336, DA024845]
- Unilever
Many candidate gene studies use 'intermediate phenotypes' instead of disease diagnoses. It has been proposed that intermediate phenotypes have simpler genetic architectures such that individual alleles account for a larger percentage of trait variance. This implies that smaller samples can be used to identify genetic associations. Pharmacogenomic drug challenge studies may be an especially promising class of intermediate phenotype. We previously conducted a series of 12 candidate gene analyses of acute subjective and physiological responses to amphetamine in 99-162 healthy human volunteers (ADORA2A, SLC6A3, BDNF, SLC6A4, CSNKIE, SLC6A2, DRD2, FAAH, COMT, OPRMI). Here, we report our attempt to replicate these findings in over 200 additional participants ascertained using identical methodology. We were unable to replicate any of our previous findings. These results raise critical issues related to non-replication of candidate gene studies, such as power, sample size, multiple testing within and between studies, publication bias and the expectation that true allelic effect sizes are similar to those reported in genome-wide association studies. Many of these factors may have contributed to our failure to replicate our previous findings. Our results should instill caution in those considering similarly designed studies. Neuropsychopharmacology (2013) 38, 802-816; doi:10.1038/npp.2012.245; published online 16 January 2013
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据